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ABSTRACT
Background: We recently demonstrated that the vitamin A derivative etretinate was clinically effective in the
treatment of skin disorders in patients with systemic sclerosis (SSc). The aim of the present study is to investi-
gate whether the oral treatment with etretinate improves sclerosis in bleomycin (BLM)-induced sclerotic skin
mice.
Methods: BLM-induced sclerotic skin mice were treated orally with 10 mgkg etretinate for 1 to 28 days. One
control group received only the vehicle, 50 μl peanut oil, while another group received no agents. BLM-treated
skin was removed and dermal thickness was measured histologically . Histopathological observation and
TUNEL assay were also studied. Messenger RNA (mRNA) ratios for procollagen α 1 (I) chain to β actin from
etretinate-treated and control mice were quantified at 1, 6, 14, and 28 days post-treatment, using quantitative
RT-PCRs.
Results: There was a significant decrease in mean dermal thickness (P < 0.05) and changes in collagen bun-
dles in the etretinate-treated mice group for a 28-day period compared to control groups. TUNEL assay showed
that the density of TUNEL-positive cells in the dermis of etretinate-treated mice for a 14-day period was signifi-
cantly increased (P < 0.05). The ratio of procollagen α 1 (I) chain to β actin mRNA from etretinate-treated mice
for a 1-day period decreased significantly compared to that of the control mice, but the ratio from etretinate-
treated mice for a 14-day period increased significantly (P < 0.05).
Conclusions: Etretinate improved BLM-induced scleroderma. These results suggest that etretinate can be
applied to the treatment of SSc skin disorders.
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INTRODUCTION
Systemic sclerosis (SSc) is a connective tissue disor-
der characterized by the accumulation of an exces-
sive extracellular matrix and vascular damage in vari-
ous organs. The pathogenesis of SSc is not clear ,
however, involvement of SSc fibroblast action and re-
lated mechanisms on the maintenance of fibrosis
have been suggested, especially in vitro. Expression
of type I collagen , fibronectin , tissue inhibitors of
metalloproteinase , and other enzymes are upregu-
lated by skin fibroblasts in SSc patients.1-4 Some cy-
tokines such as interleukin-4 and -6, whose expres-
sion is upregulated in SSc patients, induce fibroblast
mediated collagen production.5 Transforming growth
factor β and connective tissue growth factor play im-
portant roles in fibrosis or in the maintenance of fi-
brosis in SSc patients.6,7
Etretinate, a Vitamin A derivative, is also known as
retinoic acid. It is typically used in the treatment of
psoriasis, pustulosis palmaris et plantaris, and other
conditions. Etretinate reduces the production of kera-
tin, suppresses keratinization, and normalizes epider-
mal cell turnover. Some reports have indicated that
retinoic acids inhibit collagen synthesis or the prolif-
eration of normal and SSc human skin fibroblasts in
culture.8,9 In the serum of psoriasis patients treated
with etretinate, propeptide type I procollagen levels
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are reduced.10 Furthermore, retinoids are modulators
of immune responses and apoptosis. In several case
reports, systemic treatment with retinoic acids such
as etretinate, tretinoin, and isotretinoin was associ-
ated with a decrease in skin thickness and improve-
ments in skin disorders such as localized
scleroderma and lichen sclerosus,11 SSc,12 scleroder-
matous chronic graft-versus-host disease.13 Another
case study showed that topical retinoic acid treatment
was effective in treating SSc and morphea skin sclero-
sis.14 We recently showed that 5 out of 7 SSc patients
treated systemically with etretinate and 3 out of 5 pa-
tients treated systemically with etretinate and corti-
costeroids, immunosuppressants, or D-penicillamine
or other combinations demonstrated significantly im-
proved skin disorders, and the mean modified Rod-
nan total skin thickness scores of 12 SSc patients
treated with etretinate orally using ordinary doses de-
creased significantly.15
Bleomycin (BLM) is known to produce serious
side effects including induction of induce pulmonary
fibrosis. Yamamoto et al.16 developed a mouse model
of sclerotic skin using subcutaneous injections of
BLM was established by In this model, dermal thick-
ness and skin collagen was significantly increased
compared to control and FasFas ligand mediated
apoptosis of infiltrating cells was suggested to be in-
volved in the pathogenic mechanism.16,17
We investigated whether oral treatment of etreti-
nate improved sclerosis in BLM-induced sclerotic
skin model mice and whether the density of apoptotic
cells in BLM-treated dermis and the expression level
of procollagen messenger RNA (mRNA) changed .
Furthermore we studied in detail the histopathologi-
cal features using Masson-Trichrome staining in or-
der to confirm whether the changes of dermal thick-
ness were due to the changes of collagen bundles．
METHODS
MICE
We purchased specific pathogen-free 6-week-old fe-
male BALBc mice weighing approximately 20 g
from Japan SLC. Inc . (Hamamatsu , Japan) . They
were maintained in our laboratory animal center un-
der standard conditions at libitum during all treat-
ment procedures.
TREATMENTS
Etretinate was kindly provided as a gift from F .
Hoffman-La Roche Ltd (Basel , Switzerland ) , and
BLM was kindly provided as a gift from NIPPON
KAYAKU CO., LTD. (Tokyo, Japan). Peanut oil was
purchased from Sigma-Aldrich (St. Louis, MO, USA).
All mice received daily doses of 10 μg BLM diluted in
100 μl phosphate-buffered saline (PBS) injected sub-
cutaneously into a portion of shaved back skin for 4
weeks. Mice were divided into 3 groups. On the day
following the final BLM treatment , one group was
treated daily with oral 10 mgkg etretinate diluted in
50 μl peanut oil (B→E). Another control group re-
ceived only the vehicle, 50 μl peanut oil (B→P), while
another group received no agents (B→Non). Treat-
ments were continued for 1 to 28 days. Mice were
sacrificed the day following these treatments, and 5
mm punch biopsies of the injected sites were exam-
ined. Dorsal skin from mice which had completed the
entire BLM treatment was also removed as a starting
point reference for the disease state (Day 0)．
MEASUREMENTS OF DERMAL THICKNESS
AND HISTOPATHOLOGICAL EXAMINATION
Biopsied skin of mice treated with etretinate, peanut
oil, or without agents for 14 and 28 days, and mice in
the group Day 0 was fixed in a 10% formalin solution,
embedded in paraffin, and stained with Haematoxylin
and Eosin and Masson-Trichrome by Narabyouri Re-
search Co., Ltd (Nara, Japan). Dermal thickness was
measured randomly in each section by ocular and ob-
jective micrometers purchased from KENIS LIM-
ITED (Osaka, Japan). The histopathological changes
were surveyed and assessed according to a qualita-
tive scoring system. Each group consisted of 6 mice．
TUNEL ASSAY
To observe dermal changes in the density of apop-
totic cells, sections of mice treated for 14 days and 28
days and in the group Day 0 were stained using a ter-
minal deoxynucleotidyl transferase (TdT)-mediated
dUNP nick end labeling ( TUNEL ) assay with
DeadEndColorimetricTUNELSystemfromPromega Cor-
poration (WI , USA) . We counted TUNEL-positive
cells randomly using ocular and objective microme-
ters. Each group consisted of 6 mice．
REVERSE TRANSCRIPTASE-POLYMERASE
CHAIN REACTION (RT-PCR)
For RT-PCR examinations, biopsied specimens were
stored at −80℃. Day 0, etretinate treated, or negative
control mouse specimens were examined after treat-
ments of 1, 6, 14, 28 days. Total RNA was extracted
from frozen biopsied specimens using a RNeasyⓇ
Mini Kit from QIAGEN K.K. (Tokyo, Japan). cDNA
was synthesized from total RNA by reverse transcrip-
tion . Quantitative PCRs were examined with a
LightCycler Quicksystem 350S from Roche Diagnos-
tics JAPAN (Tokyo , Japan ) . Specific primers and
probes for mouse β actin and procollagen α 1 ( I )
chain were purchased from NIHON GENE RE-
SEARCH LABORATORIES INC. , (Miyagi , Japan) .
These were used in combination with Lightcycler-
FastStart DNA Master Hybridization Probes from
Roche Diagnostics JAPAN . Products were electro-
phoresed in 2% agarose gels using Tris-acetate-EDTA
buffer with ethidium bromide. DNA fragments were
examined under ultraviolet light and confirmed as
single band targets. Each group consisted of 4 to 6
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Fig. 1　The histopathology of mice in each group. Histopathological findings in dorsal skin from 
BLM-induced scleroderma mice treated with etretinate (b), peanut oil (c), and without agents (d) 
for 28 days, and mice that finished the BLM treatment (a). Dermal thickness of mice treated with 
etretinate thinned compared to the other group. Biopsied specimens were stained by haematox-
ylin and eosin. Original magnification: ×40.
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Fig. 2　Changes of dermal thickness. In each group on Day 14 and the 
group treated with peanut oil and without agents on Day 28 the mean der-
mal thickness were significantly increased compared to on Day 0 (＊, 
Fisher’ sLSD test, P < 0.05). Compared to Day 0, BLM-induced sclero-
derma in control mice progressed and persisted after the subcutaneous in-
jection of bleomycin had finished. There were no significant diferences 
among mean dermal thickness of mice treated with etretinate, peanut oil, 
and without agent for 14 days. On Day 28, mean dermal thickness of mice 
treated with etretinate decreased significantly compared to the control 
groups (＊, P < 0.05) and the group treated with etretinate for 14 days (＊,  
P < 0.05).
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Fig. 3　Masson-Trichrome staining of the skin lesional. Among each group on Day 14 there were 
no diferences in the histopathological features. On Day 28 the amount and thickness of colagen 
bundles in the group treated with etretinate decreased compared to negative control groups. 
These changes are summarized in Table 1.
Day 0 B→E Day 28 B→P Day 28 B→Non Day 28
Table 1 Changes of histopathological findings. 
B→Non
Day 28
B→P
Day 28
B→E
Day 28
B→Non
 Day 14
B→P
Day 14
B→E
Day 14
→→→→→→Changes of the epidermis
↑↑↑↑↑↑↑Fragmentations of the colagen bundles
↑↑↑↑→↑↑↑↑↑↑Amount of the colagen bundles
↑↑↑↑↑↑↑↑↑↑↑Thickness of the colagen bundles
↑↑↑↑→→→Thickness of the subcutaneous tissue
→: no changes　↑: slightly increased　↑↑: increased , compared to Day 0
mice．
STATISTICS
Ratios of mRNA for procollagen α 1 (I) chain to β ac-
tin were compared using Student’s or unpaired t
tests. Other results were analyzed using Fisher’s LSD
test. P -values less than 0.05 were regarded as statisti-
cally significant．
RESULTS
The mean dermal thickness of mice which had com-
pleted the BLM treatment (Day 0) was 317.391 ±
11.771 μm (mean ± 1 S.D). The mean dermal thick-
ness of mice in the groups B→E, B→P, and B→Non
on Day 14 were 352.657 ± 44.184, 345.894 ± 51.661, or
373.672 ± 37.919 μm. There were no significant differ-
ences among these groups. On Day 28, the mean der-
mal thickness of mice in the groups B→E, B→P, and
B→Non were 305.555 ± 29.140, 371.594 ± 18.119, or
363.188 ± 25.917 μm. There was a significant improve-
ment in the group treated with etretinate compared
with other groups (P < 0.05). The mean dermal thick-
ness of mice in the groups on Day 14 and in the
groups B→P and B→Non on Day 28 increased sig-
nificantly compared to that in the group Day 0 (P <
0.05). There was a significant decrease in the group B
→E on Day 28 compared to the mean thickness in
the group B→E on Day 14 (P < 0.05)(Figs. 1,2).
Histopathological changes are summarized in Ta-
ble 1. No changes were observed in the epidermis. In
the dermis, fragmentation of collagen bundles which
was not seen in the group Day 0 appeared in several
places, particularly in the group B→E on Day 28. In
negative control groups the amount and thickness of
collagen bundles increased compared to these in the
group Day 0. While, in the group B→E on Day 28 the
amount of collagen bundles was as same degree as in
Day 0, and the thickness increased to a minimal ex-
tent as compared to the group Day 0. The fragmenta-
tion and the changes of thickness of collagen bundles
were mainly seen in the lower dermis. In each group
on Day 14 the thickness of subcutaneous tissue was
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Fig. 4　Changes in the density of TUNEL-positive cels. The mean density of the 
group treated with etretinate for 14 days was significantly increased compared with 
the other groups (＊, Fisher’ sLSD test, P < 0.05).
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Fig. 5　Changes in the ratio of the amount of mRNA for procolagen α 1(I) chain 
to β actin. The ratio of mRNA for procolagen α 1(I) chain to β actin from mice 
treated with etretinate for 1 day decreased significantly compared to that from 
negative control mice, and the ratio from mice treated with etretinate for 14 days in-
creased compared to that in control mice (＊1, Student’ st test, P < 0.05). 
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The ratio of the amount of procollagen
α 1(I) chain mRNA/  β actin mRNA
decreased compared to that in the group Day 0, but
on Day 28 the increase were observed, particularly in
the group B→E (Fig. 3, Table 1).
The density of TUNEL-positive cells in the group
B→E on Day 14 was significantly higher compared to
other groups (P < 0.05)(Fig. 4).
The ratio of mRNA for procollagen α 1 (I) chain to
mRNA for β actin from mice treated with etretinate
for 1 day period decreased significantly compared to
that in negative control mice (P < 0.05). On Day 6
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there were no significant differences. While, on Day
14, the ratio of the group B→E was more than that of
the control group (P < 0.05)(Fig. 5).
DISCUSSION
In control mice , dermal sclerosis of BLM-induced
scleroderma progressed for 14 days and was main-
tained for 28 days after the final subcutaneous BLM
injection. The same tendencies for the amount and
thickness of collagen bundles were also observed .
These results support the report that sclerosis was
expected to persist for at least 6 weeks16 and showed
that the changes of sclerosis were due to changes of
the amount of collagen. However, dermal thickness
of mice treated with etretinate for 28 days decreased
significantly compared to the other experimental
groups. The amount and thickness of collagen bun-
dles in the group treated with etretinate for 28 days
decreased and fragmentation of the collagen bundles
was prominent when compared to the negative con-
trol groups. These histological results indicated that
etretinate inhibits the effect of sclerosis due to subcu-
taneous injections of BLM.
It has been reported that BLM-induced apoptosis
of infiltrating mononuclear cells by FasFas ligand
system is related to the mechanism of sclerosis.16,17
There were no differences among the densities of
apoptotic cells in the group Day 0 and the negative
control groups. In the group treated with etretinate
for 14 days after BLM-treatment, the density was sig-
nificantly increased compared to the control groups.
Retinoic acid selectively upregulated the expression
of Fas ligand by skin fibroblasts in vitro, inhibited in-
flammatory reactions, and prolonged mice allografts
due to induction of FasFas ligand-dependent im-
munosuppression.18 We recently observed that treat-
ment with 5 mgkg etretinate induced apoptosis of
dermal infiltrating cells and treatment with 5 and 10
mgkg etretinate reduced the dermal thickness of
MRL mice.19 These results suggest that apoptosis of
infiltrating cells by etretinate inhibited the mainte-
nance of sclerosis. However, the difference between
the sclerotic effect due to apoptosis of infiltrating cells
by BLM and the softening effect due to apoptosis of
infiltrating cells by etretinate it is not known. The dif-
ference of these effects might depend on the degree
of apoptosis or the kind of apoptotic cells.
As BLM effects clearly persisted , the ratio of
mRNA for procollagen α 1 (I) chain to β actin of the
control group increased until Day 6. And the ratio of
the control group on Day 14 and 28 were decreased.
These changes were thought to be compatible with
the changes of the dermal thickness in the control
group. The ratio of mRNA for procollagen α 1 (I)
chain to β actin in mice treated with etretinate for 1-
day period was significantly lower than in negative
control mice. There was a tendency for a lower ratio
in the group treated with etretinate on Day 6, though
it was not significant . Etretinate might take effect
early in the process and reduced the expression of
procollagen α 1 (I) chain mRNA. However, on Day
14, the ratio in the group treated with etretinate was
significantly higher than that in the control group.
This result was inconsistent with the changes of the
dermal thickness and histopathological changes. This
result might be induced by the remodeling of the der-
mal construction. More studies on the changes of
mRNA expression of transforming growth factor β ,
matrix metalloproteinase, and other proteins are nec-
essary．
Some reports have stated that the effect of etreti-
nate in inhibition of collagen production and procolla-
gen mRNA in vitro was limited compared to other ret-
inoic acids.20 However, we showed clinically efficacy
with an oral treatment of etretinate,15 and recently ob-
served that treatment with etretinate reduced the der-
mal thickness of MRL mice as stated above. These re-
sults suggest that etretinate can be a useful agent for
the treatment of SSc skin disorders.
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